Claus Roehrborn, MD
Urology · Dallas, TXNPI 1174584593
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Teleflex LLC at 47.0% of the total. Reporting peaked in 2019 at $62,636 and has fallen 88.0% since, to $7,547 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $1504.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$79K
- Neotract Inc.$35K
- GSK$25K
- Boston Scientific$13K
- Boehringer Ingelheim$10K
- Procept Biorobotics Corporation$5K
- plus $1K from 16 others
Across 44 payments — averaging $2811.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teleflex LLC$68K
- Procept Biorobotics Corporation$50K
- Arrow International, Inc.$4K
- Boston Scientific$2K
What the payments were for
- Consulting fees$55,37833%
- Speaking & faculty fees$84,57650%
- Travel & lodging$26,02815%
- Food & beverage$2,4981%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 34 | $79,256 |
| Neotract Inc. | 11 | $34,834 |
| GSK | 8 | $24,832 |
| Boston Scientific | 14 | $13,346 |
| Boehringer Ingelheim | 3 | $10,153 |
| Procept Biorobotics Corporation | 3 | $4,876 |
| Medtronic | 3 | $357 |
| Angiodynamics, Inc. | 1 | $186 |
| Rochester Medical Corporation | 8 | $180 |
| AbbVie | 4 | $104 |
| Astellas Pharma US Inc | 6 | $101 |
| Pfizer | 4 | $77 |
| Myovant Sciences Inc. | 2 | $40 |
| Coloplast | 2 | $39 |
| Merck | 2 | $34 |
| Innovation Technologies Inc | 1 | $25 |
| 180 Medical, Inc. | 1 | $20 |
| Sagent Pharmaceuticals | 1 | $15 |
| Profound Medical Corp. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$96,364
- UroLift System$17,552
- APTIVUS$10,153
- JALYN$6,479
- GENERAL BPH$6,445
- REZUM$5,669
- AquaBeam Robotic System$4,876
- GENERAL - THERAPIES$764
- INTERSTIM$279
- Nanoknife$186
- LithoVue$170
How this compares
$168,530 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 129 | $85,157 |
| GemtesaVibegron | 74 | $48,124 |
| Tamsulosin Hcl | 434 | $7,574 |
| Solifenacin Succinate | 111 | $5,745 |
| Testosterone | 48 | $5,513 |
| Finasteride | 309 | $4,532 |
| Testosterone Cypionate | 72 | $4,446 |
| Silodosin | 57 | $3,581 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 121 | $2,764 |
| Bicalutamide | 100 | $2,402 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,037 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 23 | $1,705 |
| Tolterodine Tartrate ErTolterodine Tartrate | 27 | $1,542 |
| Dutasteride | 41 | $1,235 |
| Terazosin Hcl | 35 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $101 | $85,157129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Allen MoreyDallas$914K
- Vitaly MargulisDallas$555K
- Yair LotanDallas$371K
- Samantha NealonDallas$89K
- Maia VandykeDallas$79K
- Gary LemackDallas$62K
- Brian LangfordDallas$57K
- Jonathan SeamanDallas$55K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.